Navigation Links
Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Date:8/22/2013

PITTSBURGH, Aug. 22, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) providing bioequivalence study results requested by FDA for Bupropion Hydrochloride (HCl) Extended-release (ER) Tablets USP (XL), 300 mg. Bupropion HCl ER Tablets USP (XL) are the generic version of WELLBUTRIN XL® and are indicated for the treatment of major depressive disorder (MDD).(1) Mylan launched its Bupropion HCl ER Tablets USP (XL), 150 mg and 300 mg, to the U.S. market in September 2010.

In a correspondence issued December 2012, FDA requested all generic drug companies marketing a version of Bupropion HCl ER Tablets, 300 mg, to conduct a fasting bioequivalence (BE) study comparing their Bupropion HCl ER tablets, 300 mg, to GSK's WELLBUTRIN XL (Bupropion Hydrochloride Extended-release) Tablets, 300 mg. In April 2013, Mylan submitted to FDA a sANDA containing the requested study, which demonstrated bioequivalence of Mylan's Bupropion HCl ER Tablets USP (XL), 300 mg, to WELLBUTRIN XL(R) Tablets, 300 mg.

For the 12 months ending June 30, 2013, Bupropion Hydrochloride Extended-release Tablets, 150 mg and 300 mg, had U.S. sales of approximately $503.3 million, according to IMS Health.

Currently, Mylan has 179 ANDAs pending FDA approval representing $84 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $23.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we inn
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
2. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
3. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
4. Roger Graham Named President of Mylan Specialty
5. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
6. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
7. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
8. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
9. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
10. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
11. Deborah Autor, FDAs Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... 2014 The Eastern European medical device industry ... as well as new medical-device manufacturers are constantly trying ... at ways to reduce the cost incurred for placing ... of the effective means to achieve this target. This ... Eastern European and provides profiles of key distributors in ...
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... hospital acute care and gastroenterology markets, today announced that ... UBS Global Specialty Pharmaceuticals Conference in London on Wednesday, ... The presentation will be simultaneously webcast and can be ...
... 11, 2011 Doctors in Germany are among the ... States with the REVIVE™ SE, a new self-expanding blood ... clots and restore blood flow to the brain in ... Shurtleff, Inc., a global neuroscience and neurovascular company, received ...
Cached Medicine Technology:Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 2Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 3
(Date:9/30/2014)... 30, 2014 A new study ... studied the impact of stress on metabolism after eating a ... fries from a fast food restaurant, about 930 calories and ... for 20 minutes every hour for 7 hours, conducting the ... women who had experienced a stressful event in their lives ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dynamic ... have hampered growth in the Bread Production industry ... caused consumers to moderate their consumption of a ... for premium varieties shrunk the market for white ... operators proactively responded by introducing more nutritious products ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s ... medical specialty practice through a unique partnership with an ... located within the company’s Shrewsbury location and will be ... of American Heart Center, P.C., a highly regarded practice ... Integrated Medicine Alliance patients top notch cardiovascular care without ...
(Date:9/30/2014)... (FQHCs) granted new patient appointments to Medicaid beneficiaries ... primary care practices (non-FQHCs), in addition to charging ... new 10-state University of Pennsylvania study published this ... data from a previous "secret shopper" study conducted ... FQHCs community health clinics that receive federal ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UCI study uncovers important process for immune system development 2
... April 27 Estill Medical Technologies, Inc., the industry ... announces the expansion of its Thermal Angel sales and ... mortality by quickly controlling core body temperature and infection ... administration. In emergency medicine, the golden hour refers to ...
... Members to Help Raise Obesity on the Nation,s Public ... health associations and obesity experts joined the S ... P revent (STOP) Obesity Alliance today as the organization ... grappling with the high costs of weight-related health conditions ...
... illnesses in which the immune system creates autoantibodies to ... non-profit Autoimmunity Research Foundation (ARF) explain that the antibodies ... human genes and gene products by hidden bacteria. , ... bacteria capable of causing human disease, But DNA discoveries ...
... Pharmaceuticals, a division of Wyeth (NYSE: ... has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a ... of postmenopausal osteoporosis in women at increased risk ... risk treatment guidelines and assessment tool for calculating ...
... Study shows those who respond to lapatinib survive longer, , , ... be used to treat aggressive inflammatory breast cancer, suggest the ... cancer accounts for up to 6 percent of all invasive ... to the researchers. Symptoms include rapid onset of swelling, ...
... to mirror Mandela,s values NEW YORK, April 27 46664 ... the world to support the creation of an official ... Mr. Mandela,s birthday. This celebration of Nelson Mandela,s life will ... recognize their individual power to make an imprint and help ...
Cached Medicine News:Health News:Thermal Angel Supports Infection Control During the Golden Hour 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 3Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 4Health News:'Autoantibodies' may be created in response to bacterial DNA 2Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 2Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 3Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 4Health News:Drug May Help Against Inflammatory Breast Cancer 2Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 2Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 3Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 4Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 5
For universal arthroscopic meniscal repair/suture. Uses double-armed, single-throw sutures....
... Great Toe Implant (KGTI) system offers the ... the first MPJ. The implant system is ... motion. , ,The KGTI is the most ... joint (MPJ) on the market today. The ...
... Intraoperative Electrodes share similar characteristics ... main difference is that all ... numbered to assist you intraoperatively. ... designed for use with either ...
... full field digital mammography system signals ... in the world of mammography. This ... the latest advances in digital imaging ... to bring you the total solution ...
Medicine Products: